WO 2005/082416 PCT/IB2005/000100

CLAIMS

- 1. A pharmaceutical composition comprising a therapeutically effective amount of an Active Pharmaceutical Ingredient, a β-cyclodextrin, a pharmaceutically acceptable preservative, a pharmaceutically acceptable vehicle, and an optional pharmaceutically acceptable excipient, wherein the preservative demonstrates pharmaceutically acceptable antimicrobial preservative effectiveness.
- A pharmaceutical composition according to claim 1 wherein the Active
 Pharmaceutical Ingredient is a compound of Formula I,

or its pharmaceutically acceptable salts, wherein R² is selected from the group consisting of methyl, ethyl, isopropyl, *sec*-butyl and *tert*-butyl.

15

- 3. The pharmaceutical composition according to Claims 1 or 2 wherein the β-cyclodextrin is 2-hydroxypropyl- β-cyclodextrin or sulfobutyl ether-β-cyclodextrin.
- 4. The pharmaceutical composition according to any preceding claim wherein the preservative is selected from thimerosal, propylene glycol, phenol, or meta-cresol or a combination thereof.

WO 2005/082416 PCT/IB2005/000100

5. The pharmaceutical composition according to any preceding claim wherein the preservative has a binding value to the cyclodextrin that is less than a binding value of the Active Pharmaceutical Ingredient to cyclodextrin.

6. The pharmaceutical composition according to any preceding claim wherein about 1 mg/mL to about 5 mg/mL of the preservative is unsequestered in the cyclodextrin.

5

- 7. The pharmaceutical composition according to any preceding claim wherein the binding value of the Active Pharmaceutical Ingredient to cyclodextrin is between 500 M⁻¹ and 10,000 M⁻¹.
- 10 8. The pharmaceutical composition according to any preceding claim for use as a medicament.
 - 9. The use of a composition according to any of Claims 2 to 7 in the manufacture of a medicament for the treatment of a disease for which a neurokinin receptor antagonist is indicated.
- 15 10. A method for the treatment of a disease for which a neurokinin receptor antagonist is indicated in mammals comprising administering to said mammal a therapeutically effective amount of a pharmaceutical composition of any of Claims 2 to 7.